MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Galectin Therapeutics Cash and Cash Equivalents 2011-2026 | GALT
Annual Cash and Cash Equivalents Galectin Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.1 M | 25.7 M | 18.6 M | 39.6 M | 27.1 M | 47.5 M | 8.25 M | 3.05 M | 15.4 M | 25.8 M | 29.1 M | 10.5 M | 9.36 M | 6.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 47.5 M | 3.05 M | 20.1 M |
Quarterly Cash and Cash Equivalents Galectin Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.5 M | 13.8 M | 7.43 M | 15.1 M | 27.1 M | 25.6 M | 23.6 M | 25.7 M | 20.4 M | 18 M | 18 M | 18.6 M | 15.8 M | 24.2 M | 31.6 M | 39.6 M | 36.6 M | 31.6 M | 20.8 M | 27.1 M | 27.1 M | 27.1 M | 27.1 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 8.25 M | 8.25 M | 8.25 M | 8.25 M | 3.05 M | 3.05 M | 3.05 M | 3.05 M | 15.4 M | 15.4 M | 15.4 M | 15.4 M | 25.8 M | 25.8 M | 25.8 M | 25.8 M | 29.1 M | 29.1 M | 29.1 M | 29.1 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | 9.36 M | 9.36 M | 9.36 M | 9.36 M | 6.4 M | 6.4 M | 6.4 M | 6.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 47.5 M | 3.05 M | 19.6 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Grifols, S.A.
GRFS
|
980 M | $ 7.72 | 1.85 % | $ 6.83 B |  Spain |
 |
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 19.68 | 0.92 % | $ 920 M |  USA |
 |
Amarin Corporation plc
AMRN
|
135 M | $ 14.5 | 0.03 % | $ 6.02 B |  Irlanda |
 |
GlaxoSmithKline plc
GSK
|
3.4 B | $ 52.37 | 1.02 % | $ 173 B |  Britain |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
616 M | $ 221.59 | -0.13 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.39 | 1.46 % | $ 355 M | Britain |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Heron Therapeutics
HRTX
|
28.6 M | $ 0.81 | 3.74 % | $ 135 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Benitec Biopharma
BNTC
|
97.7 M | $ 11.05 | 0.64 % | $ 455 M | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Calithera Biosciences
CALA
|
59.5 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Immunovant
IMVT
|
714 M | $ 24.1 | 4.85 % | $ 3.65 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | USA |
 |
Incyte Corporation
INCY
|
3.1 B | $ 90.36 | -0.47 % | $ 17.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
8.91 M | $ 0.74 | -9.75 % | $ 1.81 M | Canada |
 |
INmune Bio
INMB
|
35.8 M | $ 1.17 | -0.43 % | $ 21 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
143 M | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
7.8 M | $ 2.13 | 1.91 % | $ 199 M | Israel |
 |
Innate Pharma S.A.
IPHA
|
66.4 M | $ 1.35 | 15.38 % | $ 235 M | France |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
26.3 M | $ 4.43 | 4.6 % | $ 735 M | Canada |
 |
Inventiva S.A.
IVA
|
96.6 M | $ 6.1 | 5.5 % | $ 138 M | France |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |